galactose has been researched along with Cross Infection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gursoy, T; Karatekin, G; Ovalı, F; Serce, O; Topcuoglu, S | 1 |
| Coria, P; del Valle, G; Moreno, C | 1 |
| Fortún, J; Fresco, G; Meije, Y; Moreno, S | 1 |
| Andrés, R; Elías, T; Fernandez de Orueta, L; Pintado, V | 1 |
| Hermans, G; Lagrou, K; Maertens, J; Meersseman, W; Spriet, I; Van Wijngaerden, E; Vanderschueren, S; Verbeken, E; Wilmer, A | 1 |
| Anaissie, EJ | 1 |
1 review(s) available for galactose and Cross Infection
| Article | Year |
|---|---|
[Aspergillosis. Clinical forms and treatment].
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Cross Infection; Drug Resistance, Multiple, Fungal; Endocarditis; Endophthalmitis; Fungemia; Galactose; Humans; Immunocompromised Host; Mannans; Neuroaspergillosis; Postoperative Complications; Pulmonary Aspergillosis; Radiography; Risk Factors; Salvage Therapy; Species Specificity; Vulnerable Populations | 2012 |
1 trial(s) available for galactose and Cross Infection
| Article | Year |
|---|---|
A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics.
Topics: Bifidobacterium; Cross Infection; Disease Outbreaks; Galactose; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infection Control; Lactobacillus; Oligosaccharides; Probiotics; Risk Factors; Turkey; Vancomycin-Resistant Enterococci | 2015 |
4 other study(ies) available for galactose and Cross Infection
| Article | Year |
|---|---|
[Economical evaluation of the treatment of invasive aspergillosis in pediatric oncology patients. Santiago. Chile].
Topics: Adolescent; Antifungal Agents; Antigens, Fungal; Aspergillosis; Case-Control Studies; Child; Chile; Cross Infection; Female; Galactose; Health Care Costs; Humans; Immunocompromised Host; Male; Mannans; Neoplasms; Opportunistic Infections; Retrospective Studies | 2010 |
[Vertebral aspergillosis in a cirrhotic patient: an uncommon cause of spondylitis].
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Biomarkers; Cross Infection; Fatal Outcome; Galactose; Haemophilus influenzae; Hepatitis C, Chronic; Humans; Immunocompromised Host; Liver Cirrhosis; Low Back Pain; Lumbar Vertebrae; Male; Mannans; Middle Aged; Multiple Organ Failure; Opportunistic Infections; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Spondylitis; Triazoles; Voriconazole | 2012 |
Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients.
Topics: Adult; Aged; Aspergillosis; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cause of Death; Cross Infection; Diagnosis, Differential; Female; Galactose; Hospital Mortality; Humans; Intensive Care Units; Lung; Lung Diseases, Fungal; Male; Mannans; Middle Aged; Mycological Typing Techniques; Opportunistic Infections; Pneumonia, Ventilator-Associated; Predictive Value of Tests; Prospective Studies; Survival Rate; Tomography, X-Ray Computed | 2008 |
A bad bug takes on a new role as a cause of ventilator-associated pneumonia.
Topics: Aspergillosis; Aspergillus; Bronchoalveolar Lavage Fluid; Cross Infection; Galactose; Hospital Mortality; Intensive Care Units; Lung Diseases, Fungal; Mannans; Opportunistic Infections; Pneumonia, Ventilator-Associated; Predictive Value of Tests; Survival Rate | 2008 |